Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

Orforglipron carried more side effects, however ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: You can get semaglutide injections (Ozempic® and Wegovy®) and oral semaglutide (Rybelsus®). Injections are usually more ...

Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis. The drug behind Ozempic and Wegovy ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist. Topline data were ...

For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) ...

Please provide your email address to receive an email when new articles are posted on . Adults receiving nimacimab plus semaglutide had a 2.95 percentage point greater weight loss than semaglutide ...

Semaglutide (Ozempic®, Wegovy®, Rybelsus®) comes in both injection and oral form. But beyond how you take it, what’s the difference? And which form is more effective for weight loss? Semaglutide ...

Semaglutide is a glucagon-like peptide-1 receptor (GLP-1) medication primarily used to manage obesity and diabetes. The U.S. Food and Drug Administration (FDA) also has approved it under the brand ...